Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation Via Protease Activated Receptor-1.

Conclusions: Here we identified FXa as potent platelet agonist that acts through PAR1. Therefore, RIVA exerts an antiplatelet effect that together with its well-known potent anticoagulatory capacity might lead to reduced frequency of atherothrombotic events and improved outcome in patients.
PMID: 31859592 [PubMed - as supplied by publisher]

Source: Circulation Research - December 19, 2019 Category: Cardiology Authors: Petzold T, Thienel M, Dannenberg LK, Mourikis P, Helten C, Ayhan A, M'Pembele R, Achilles A, Trojovsky K, Konsek D, Zang Z, Regenauer R, Pircher J, Ehrlich A, Lüsebrink E, Nicolai L, Stocker T, Brandl R, Röschentaler F, Strecker J, Saleh I, Spannagl M, Tags: Circ Res Source Type: research